Item 2.05 Costs Associated with Exit or Disposal Activities.

As previously announced, La Jolla Pharmaceutical Company (the "Company") ceased the development of Riquent following a determination in February 2009 that the continuation of the ASPEN clinical trial would be futile. As a result of the decision to abandon the Riquent program, and in an effort to cut ongoing operating expenses, the Company terminated approximately 75 employees on April 20, 2009. Following this reduction in force and the termination of Riquent development activities, the Company is focusing its efforts on maximizing the value of its remaining assets, including its SSAO program, and is considering strategic transactions. As a result of the reduction in force, the Company expects to record a one-time charge of approximately $1.2 million in the quarter ending June 30, 2009.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the Company's efforts to reduce ongoing operating expenses, as described above in Item 2.05, the employment of the following executives of the Company was terminated as of April 20, 2009: Niv E. Caviar, Executive Vice President, Chief Business & Financial Officer; Michael J.B. Tansey, M.D., Ph.D., Executive Vice President, Chief Medical Officer; and Josefina T. Elchico, Vice President, Quality Operations.

Following the departure of Mr. Caviar, Gail A. Sloan, Vice President of Finance, will serve as the Company's principal financial officer and will continue to serve as the Company's principal accounting officer.

---

Top of the Form